ML22166A396
| ML22166A396 | |
| Person / Time | |
|---|---|
| Issue date: | 07/26/2022 |
| From: | Kevin Williams Office of Nuclear Material Safety and Safeguards |
| To: | Orzech E Certification Board of Nuclear Endocrinology |
| J. Fisher, NMSS/MSST/MSEB | |
| References | |
| Download: ML22166A396 (4) | |
Text
July 26, 2022 Dr. Eric Orzeck Past Chair, Certification Board of Nuclear Endocrinology ATTN: The Endocrine Center 10837 Katy Freeway, Suite 200 Houston, TX 77079
SUBJECT:
CERTIFICATION BOARD OF NUCLEAR ENDOCRINOLOGY, TERMINATION OF NRC RECOGNITION LETTER
Dear Dr. Orzeck:
The purpose of this letter is to inform you that the U.S. Nuclear Regulatory Commission (NRC) has terminated its recognition of the Certification Board of Nuclear Endocrinologys (CBNE) certification processes. This termination of CBNEs recognition is based on the lack of response to NRC letters, on information provided by the American Association of Clinical Endocrinology (AACE), and on the administrative dissolution of CBNE by the State of Florida.
Given CBNEs status, the CBNE Nuclear EndocrinologyLow Dose certification process no longer satisfies the board recognition criteria in Title 10 of the Code of Federal Regulations (10 CFR) 35.190, "Training for uptake, dilution, and excretion studies," and 10 CFR 35.392, "Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)." In addition, the CBNE Nuclear EndocrinologyHigh Dose certification process no longer satisfies the board recognition criteria in 10 CFR 35.190, "Training for uptake, dilution, and excretion studies," and 10 CFR 35.394, "Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries)."
On May 18, 2022, the NRC sent a letter to CBNE, which requested confirmation of CBNEs inactive status and requested the date of the last CBNE examination. This letter was addressed to you, as the last known chair of the CBNE, and was sent to your medical practice. The letter is in the NRCs Agencywide Documents Access and Management System (ADAMS), Accession No. ML22129A095. A response was not received. An NRC letter dated March 15, 2022 (ML22069A714), was sent to the last known CBNE mailing address and was returned to sender.
The NRC attempted to contact past CBNE board members at their medical practices but was unable to obtain necessary information. One past board member did respond (ML22159A276) but did not send confirmation that the specialty board had disbanded and did not provide the date of the last CBNE examination.
Through a CBNE letter dated February 22, 2011 (ML111260527), the staff were aware of a relationship between CBNE and AACE. The staff contacted AACE, and the staff learned from AACE that CBNE had disbanded. AACE did not have information regarding when the last
E. Orzeck 2 course or CBNE examination was provided. Florida Department of State records (ML22187A012) established that CBNE was administratively dissolved on September 27, 2019.
Because of the lack of response to the NRC letters, information provided by AACE, and the administrative dissolution of CBNE by the State of Florida, the NRC has concluded that the CBNE has disbanded and has terminated its recognition. The NRC will no longer recognize CBNE certifications issued after September 27, 2019. The NRC based this date on the Florida Department of State records, which confirmed that CBNE is inactive.
Candidates that were granted certification from the CBNE between January 1, 2013, when CBNEs processes were recognized by the NRC (ML13204A063), and September 27, 2019, will continue to be recognized by the NRC. The 7-year requirement in 10 CFR 35.59, Recentness of training, will continue to apply to candidates granted certification from CBNE between January 1, 2013, and September 27, 2019. Candidates that received CBNE certification outside of this time interval may seek certification through a different NRC-recognized specialty board or through the NRCs alternate training and experience pathway if they are seeking an Authorized User position.
In the future, CBNE may re-apply for NRC recognition if it becomes active and satisfies the board recognition criteria in 10 CFR Part 35, Medical Use of Byproduct Material.
In accordance with 10 CFR 2.390, Public inspections, exemptions, requests for withholding, a copy of this letter, along with your response letter, will be made available electronically for public inspection in the NRC Public Document Room or in the NRCs ADAMS, accessible from the NRC website at http://www.nrc.gov/reading-rm/adams.html.
For further information or for questions, please contact Maryann Ayoade at (301) 415-0862 or via email at Maryann.Ayoade@nrc.gov, or Jennifer Fisher at (301) 415-1456 or via email at Jennifer.Fisher@nrc.gov.
Clark, Theresa signing on behalf of Williams, Kevin on 07/26/22 Kevin Williams, Director Division of Materials Safety, Security, State, and Tribal Programs Office of Nuclear Material Safety and Safeguards cc: American Association of Clinical Endocrinology 245 Riverside Avenue, Suite 200 Jacksonville, FL 32202 membership@aace.com Dr. Mark Lupo Past CBNE Board Member Thyroid and Endocrine Center 3050 Bee Ridge Road Sarasota, FL 34231
E. Orzeck 3 Dr. Steven Artz Past CBNE Board Member 3100 MacCorkle Avenue SE, Suite 700 Charleston, WV 25304 Dr. Carlos Hamilton Past CBNE Board Member 6410 Fannin Street, Suite 1228 Houston, TX 77030
ML22166A396 OFFICE NMSS/MSST NMSS/MSST NMSS/MSST NMSS/MSS NMSS/MSST T T Clark for NAME J Fisher M Ayoade C Valentin-Rodriguez C. Einberg K Williams DATE 07/14/2022 07/20/2022 07/21/2022 07/21/2022 07/26/2022